Silk Technologies, Ltd.

Silk Technologies, Ltd. focuses on developing and commercializing Silk-Derived Protein (SDP) products for diverse applications, enhancing formulations in sectors such as medical, consumer goods, and animal health. Silk Technologies, Ltd. develops Silk-Derived Protein (SDP) products with a headquarters in Plymouth, US.

Founded in 2013, the company has completed two deals, with the most recent being a Series B funding round on April 16, 2019, where they raised USD 6. 2 mn led by Skyview Capital. The company was founded by Brian Lawrence, who has a history of entrepreneurial ventures, although details on prior startups are not available. Silk Technologies, Ltd.

specializes in Silk-Derived Protein (SDP) products aimed at diverse applications. Their offerings include SDP ingredients that enhance formulation properties in medical devices, drug delivery vehicles, cosmetics, supplements, and more. By leveraging proprietary technology, they assist clients in developing healthier products while minimizing synthetic ingredients. They serve a global clientele, focusing on markets in North America, Europe, and Asia, where there is a demand for sustainable product development.

Silk Technologies primarily generates revenue through business-to-business transactions with manufacturers and developers. They establish partnerships with clients incorporating SDP into their products, potentially involving licensing agreements or direct sales. Their pricing structure may include bulk pricing for SDP ingredients, allowing clients to integrate innovative materials cost-effectively. The company's proprietary technology positions it competitively in the market, aiming to enhance product efficacy and safety across various sectors.

Silk Technologies plans to leverage its recent Series B funding of USD 6. 2 mn to support new product development and expansion into additional markets. They intend to introduce new SDP formulations tailored for health-conscious consumers and explore opportunities in emerging markets in Europe and Asia by the end of 2021. This funding will enable the company to enhance its research and development capabilities, facilitating the launch of innovative products that meet the evolving demands of their clientele.